Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
По алфавиту
- A
- B
- C
- D
- E
- F
- G
- H
- I
- J
- K
- L
- M
- N
- O
- P
- Q
- R
- S
- T
- V
- W
- X
- Y
- Z
- І
- А
- Б
- В
- Г
- Д
- Е
- Ж
- З
- И
- К
- Л
- М
- Н
- О
- П
- Р
- С
- Т
- У
- Ф
- Х
- Ц
- Ч
- Ш
- Щ
- Э
- Ю
- Я
- Весь список
Warning: mb_strpos(): Empty delimiter in /var/www/u1363561/data/www/biotech.spb.ru/wp-content/plugins/code-snippets/php/snippet-ops.php(581) : eval()’d code(4) : eval()’d code on line 13
R A Figlin, W C Pierce, A Belldegrun
Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinomaSemin Oncol. 1993 Dec;20(6 Suppl 9):11-5.
R Figlin, B Gitlitz, J Franklin, F Dorey, N Moldawer, J Rausch, J deKernion, A Belldegrun
Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patientsCancer J Sci Am. 1997 Dec;3 Suppl 1:S92-7.
R M Bukowski
Cytokine combinations: therapeutic use in patients with advanced renal cell carcinomaSemin Oncol. 2000 Apr;27(2):204-12.
R M Bukowski
Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2Cancer. 1997 Oct 1;80(7):1198-220.
Rai A., Chakravarty A.K.
Homing of radiolabelled recombinant interleukin-2 activated natural killer cells and their efficacy in adoptive immunotherapy against murine fibrosarcoma.J Biosci. 2007 Dec;32(7):1299-305.
Ratto GB, Costa R, Maineri P et all.
Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot study.Int J Immunopathol Pharmacol. 2011 Oct-Dec;24(4):1005-16.
Ricci M.S., Sarkar CA., Fallon E.M., Lauffenburger D.A., Brems D.N.
pH Dependence of Structural Stability of interleukin-2 and Granulocyte Colony-Stimulating Factor.Protein Sci. 2003 May;12(5):1030-8. doi: 10.1110/ps.0230103.
Robert O Dillman, Michael C Wiemann, D Fritz Tai, Carol B Depriest, Gamini Soori, James J Stark, Khosrow Mahdavi, Curtis K Church
Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/continuous infusion interleukin-2 in the treatment of renal cell carcinoma: final results of Cancer Biotherapy Research Group 95-09Cancer Biother Radiopharm. 2006 Apr;21(2):130-7.
Roman Hájek, Daniela Zácková, Tomás Büchler, Miroslav Penka, Eva Krahulcová, Zdenĕk Korístek, Jaroslava Vinklárková, Jiri Adler, Eva Janovská, Karel Indrák, Edgar Faber, Michal Doubek, Martin Klabusay, Alexandra Oltová, Petr Kuglík, Ludmila Bourková, Ladi
Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administrationMed Oncol. 2003;20(1):69-76.
Rosmely Hernandez, Kathryn M LaPorte, Sunnie Hsiung, Alicia Santos Savio, Thomas R Malek
High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4 + and CD8 + neoantigen-specific T cells to promote antitumor immunityJ Immunother Cancer. 2021 Sep;9(9):e002865.
Rosmely Hernandez, Kevin H Toomer, Janika Põder, Alicia Santos Savio, Sunnie Hsiung, Thomas R Malek
Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8 + T cells to enhance antitumor immunityCancer Immunol Immunother. 2021 Apr;70(4):909-921.
Ruihe Wu, Yanfei Mu, Jinfang Zhao et al.
Short-term and low-dose IL-2 therapy increases the reduced Treg cells in patients with microscopic polyangiitis.Autoimmunity Reviews. — 2022. — Vol. 21, Issue 9, September, P. 103156.
Ruihe Wua , Na Li, Xiangcong Zhao, Tingting Ding et al. 
PDF
Autoimmunity Reviews. — 2020. — Volume 19, Issue 10, October, 102645.
Ruimei Zhang, Xiangyu Xi, Chunying Wang et al. PDF
Терапевтические эффекты рекомбинантного интерлейкина-2 человека в качестве дополнительной иммунотерапии против туберкулеза: систематический обзор и мета-анализ.
PLoS One. 2018 Jul 19;13(7):e0201025. doi: 10.1371/journal.pone.0201025. eCollection 2018.
Ruth Whittington, Diana Faulds
Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancerDrugs. 1993 Sep;46(3):446-514.
В соответствии с п. 1 ст. 64 Федерального закона от 12.04.2010 № 61-ФЗ "Об обращении лекарственных средств" лекарственные препараты, находящиеся в обращении на территории Российской Федерации, подлежат мониторингу безопасности в целях выявления возможных негативных последствий их применения, предупреждения пациентов и их защиты от применения таких препаратов.